Teva VP Ika Abravanel resigns
CartiHeal's preclinical trial of its articular cartilage repair product, Agili-C, was successful, and enough for EU CE Mark certification.
Cartilage implant company CartiHeal Ltd. has raised $5 million from Accelmed, the fund of Moshe (Mori) Arkin and Uri Geiger, and Access Medical Ventures, a US fund run by Israelis Limor Sandach, Dvir Keren, and Michael Tal. CartiHeal is a graduate of Peregrine Ventures' Incentive Technological Incubator.
CartiHeal CEO Nir Altschuler, a biomedical engineer, founded the company in 2009, on the basis of a concept discovered at Ben Gurion University of the Negev. The company previously raised $1.2 million.
CartiHeal's preclinical trial of its articular cartilage and osteochondral defect repair product, Agili-C, was successful, and enough for EU CE Mark certification. Altschuler said, "It is very unusual to obtain CE Mark without clinical trials, but the preclinical trial results were good enough."
CartiHeal will use the proceeds to financing marketing of its product in Europe, which it plans to begin in a year. The US is not a target market for now, due to the investment needed for a US Food and Drug Administration (FDA) protocol clinical trial, and the uncertainty of the registration. The product is also certified in Israel.
The cartilage reconstruction market is experimental, but promising. Companies developing stem cell-based products are the main companies in this segment, including Israel's Carticure Ltd., Regentis Biomaterials Ltd., and Prochon Biotech Ltd., which merged with a US company last year and is closest to bringing a product to market.
Companies in the cartilage reconstruction segment estimate the market at $1.6 billion a year, although most products are still only experimental.
Agili-C is in two parts. One made of aragonite, and the other made of aragonite and hyaluronic acid is biocompatible and biodegradable. It does not include living tissue, in contrast to most innovative products under development. "We found that these materials attract stem cells from the bone marrow, so that only cells in aragonite area turn into bone, and cells in the area of the aragonite and hyaluronic acid turn into cartilage," says Altschuler.
He says that the Agili-C is implanted through minimally invasive surgery, similar to an injection. "The cells gradually dissolve the implant, and within a short time, the implant can bear the body's weight and regular activity can be resumed," he says.
Published by Globes [online], Israel business news - www.globes-online.com - on January 31, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.